Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

INTRODUCTION: No head-to-head studies have compared inotuzumab ozogamicin (InO) and blinatumomab (Blina) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). Indirect treatment comparisons (ITCs), namely network meta-analysis (NMA), anchored ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Proskorovsky, Irina, Su, Yun, Fahrbach, Kyle, Vandendries, Erik, Pagé, Véronique, Onyekwere, Uchenna, Wang, Yunyang, Cappelleri, Joseph C., Stelljes, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822860/
https://www.ncbi.nlm.nih.gov/pubmed/31140123
http://dx.doi.org/10.1007/s12325-019-00991-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822860/
https://www.ncbi.nlm.nih.gov/pubmed/31140123
http://dx.doi.org/10.1007/s12325-019-00991-w

Ejemplares similares